Cytokine Adsorption: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -72% 2 83 Improvement, Studies, Patients Relative Risk Mortality -72% 2 83 RCTs -72% 2 83 RCT mortality -72% 2 83 Late -72% 2 83 Cytokine Adsorption for COVID-19 c19early.org December 2025 Favorscytokine adsorption Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 studies c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 mortality results c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 serious outcomes c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 Randomized Controlled Trials c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 RCT mortality results c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Cytokine adsorption COVID-19 outcomes c19early.org December 2025 Favors cytokine adsorption Favors control